文献速递新生儿

新生儿戒断综合征的药物治疗:系统综述与网络Meta分析

Pharmacological Treatments for Neonatal Abstinence Syndrome: A Systematic Review and Network Meta-analysis.
PubMed 文献 · JAMA Pediatr · 2019-01-01

该系统综述与网络Meta分析纳入18项随机临床试验(N=1072),比较多种药物对新生儿戒断综合征的治疗效果。结果显示舌下丁丙诺啡在缩短治疗时长和住院时长方面可能最优,但证据存在局限性,需大规模多中心试验验证;吗啡在缩短治疗时长和住院时长方面排名最低。

要点

  • 舌下丁丙诺啡可能为缩短治疗时长和住院时长的最优药物。
  • 吗啡在缩短治疗时长和住院时长方面排名最低。
  • 证据受限于试验数量少和精确性不足,需大规模多中心试验验证。

核心结论

  • 当前证据提示舌下丁丙诺啡是新生儿戒断综合征的最优治疗,但局限性较大,广泛采用需大规模多中心试验。
  • 吗啡在缩短治疗时长和住院时长方面排名最低。

研究设计与样本

  • 系统综述与网络Meta分析,检索Medline、Embase、Cochrane CENTRAL、Web of Science和ClinicalTrials.gov至2018年6月。
  • 纳入18项随机临床试验,共1072例新生儿戒断综合征患者。
  • 采用固定效应模型合并数据,使用Cochrane偏倚风险工具评估质量。

主要发现

  • 舌下丁丙诺啡对比吗啡的治疗时长平均差为-12.75天(95%CI,-17.97至-7.58),中位排名1(3-1)。
  • 舌下丁丙诺啡对比吗啡的住院时长平均差为-11.43天(95%CI,-16.95至-5.82),中位排名1(3-1)。
  • 舌下丁丙诺啡对比吗啡的辅助治疗需求比值比为1.23(95%CI,0.46-3.44),中位排名3(5-1)。
  • 结果对偏倚稳健但对不精确性敏感。

关键数值与推荐

  • 主要结局为治疗时长;次要结局包括住院时长、辅助治疗需求和不良事件。
  • 纳入分析的治疗包括丁丙诺啡、可乐定、稀释阿片酊及可乐定、稀释阿片酊、吗啡、美沙酮和苯巴比妥。

临床怎么用

  • 舌下丁丙诺啡可能缩短治疗时长和住院时长,但需考虑证据局限性。
  • 吗啡作为多数医院标准治疗,在缩短治疗时长和住院时长方面排名最低。

局限性

  • 纳入试验数量少,数据采用固定效应模型合并。
  • 结果对不精确性敏感,广泛 adoption 需大规模多中心试验。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Incidence of neonatal abstinence syndrome is rising rapidly, and optimal pharmacotherapy may meaningfully reduce length of treatment. OBJECTIVE: To compare pharmacological therapies for neonatal abstinence syndrome. DATA SOURCES: Systematic review and network meta-analysis of Medline (1946-June 2018), Embase (1974-June 2018), Cochrane CENTRAL (1966-June 2018), Web of Science (1900-June 2018), and ClinicalTrials.gov (June 2018). STUDY SELECTION: Randomized clinical trials of pharmacological treatments for neonatal abstinence syndrome alone or in combination with adjuvant treatments. Abstract, title, and full-text screening were conducted independently by 2 reviewers (T.D. and C.G.). DATA EXTRACTION AND SYNTHESIS: Data extraction was conducted independently by 2 reviewers (T.D. and C.G.) according to Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA)-Network Meta-Analyses guidelines. Quality was assessed with the Cochrane Risk of Bias tool and data were pooled with fixed-effect models as a result of the low number of trials that were included in the analysis. MAIN OUTCOMES AND MEASURES: The primary outcome was the length of treatment. The length of stay, need for adjuvant therapy, and adverse events were considered as secondary outcomes. RESULTS: Eighteen trials (N = 1072) were eligible for inclusion. The treatments that were included in the length of treatment analysis were buprenorphine, clonidine, diluted tincture of opium and clonidine, diluted tincture of opium, morphine, methadone, and phenobarbital. Sublingual buprenorphine was considered the optimal treatment for a reduction in the length of treatment (days: mean difference vs morphine, -12.75 [95% CI, -17.97 to -7.58]; median rank, 1 [3-1]) and length of stay (days: mean difference vs morphine, -11.43 [95% CI, -16.95 to -5.82]; median rank, 1 [3-1]) but not the need for adjuvant treatment (odds ratio vs morphine, 1.23 [95% CI, 0.46-3.44]; median rank, 3 [5-1]). The results were robust to bias but sensitive to imprecision. CONCLUSIONS AND RELEVANCE: The current evidence suggests that buprenorphine is the optimal treatment for neonatal abstinence treatment, but limitations are considerable and wide-scale adoption requires a large multisite trial. Morphine, which is considered standard of care in most hospitals, was the lowest-ranked opioid for length of treatment and length of stay.

来源:JAMA Pediatr,查看原文。版权归原作者所有。

引用

  1. Disher T, Gullickson C, Singh B, et al. Pharmacological Treatments for Neonatal Abstinence Syndrome: A Systematic Review and Network Meta-analysis. JAMA Pediatr. 2019. PMID: 30667476. doi:10.1001/jamapediatrics.2018.5044

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。